The ongoing phase III MK‐2870‐004 study (NCT06074588) will evaluate the efficacy and safety of MK‐2870 versus chemotherapy for previously TKI‐treated NSCLC with EGFR mutations or other genomic alterations in ALK, ROS1, BRAF V600E, NTRK, MET exon 14 skipping, or RET and those with less common EGFR mutations (exon 20 S768I, exon 21 L861Q, and/or exon 18 G719X). Here, ALK is linked to non-small cell lung carcinoma.